Chiauranib - Chipscreen Biosciences

Drug Profile

Chiauranib - Chipscreen Biosciences

Alternative Names: CS-2164

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chipscreen Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Aurora kinase B inhibitors; Mitosis inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 09 Nov 2017 Phase-I clinical trials in Small cell lung cancer (Second-line therapy or greater) in China (PO) (NCT03216343)
  • 16 Aug 2017 Chipscreen Biosciences plans a phase I trial for Hepatocellular carcinoma (Late-stage disease) in (NCT03245190)
  • 11 Jul 2017 Chipscreen Biosciences plans a phase Ib trial in Small cell lung cancer (Second-line therapy or greater) (PO) (NCT03216343)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top